Afuco™ Anti-C5 ADCC Recombinant Antibody (Eculizumab), ADCC Enhanced (CAT#: AFC-TAB-008)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human C5. Eculizumab also is the first agent approved for the treatment of atypical hemolytic uremic syndrome (aHUS), an ultra-rare genetic disease that causes abnormal blood clots to form in small blood vessels throughout the body, leading to kidney failure, damage to other vital organs and premature death.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
RNA Expression

Specifications

  • Immunogen
  • Human C5 protein emulsified with complete Fraud`s adjuvant
  • Host Species
  • Human
  • Derivation
  • Humanized (from mouse)
  • Type
  • ADCC enhanced antibody
  • Species Reactivity
  • Human
  • Clone
  • Eculizumab
  • Applications
  • ELISA, FC, IP, FuncS, IF, Neut
  • Conjugate
  • Unconjugated
  • Trade name
  • Soliris
  • Generic Name
  • Eculizumab
  • Related Disease
  • Neuromyelitis optica (NMO)

Product Property

  • Purity
  • >95% by SDS-PAGE
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

  • Alternative Names
  • Eculizumab; soliris; 219685-50-4; h5G1.1; DB01257 C5; complement component 5; complement C5; CPAMD4; anaphylatoxin C5a analog; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4; FLJ17816; FLJ17822; MGC142298;

Related Resources

  • Biosimilar Overview
  • Related Diseases
Please refer to Eculizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Eculizumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Eculizumab"

Anti-Human C5 Recombinant Antibody (Eculizumab)
Recombinant monoclonal antibody to Human C5. Eculizumab also is the first agent approved for the treatment of atypical hemolytic uremic syndrome (aHUS), an ultra-rare genetic disease that causes abnormal blood clots to form in small blood vessels throughout the body, leading to kidney failure, damage to other vital organs and premature death.

See other products for "Clone Eculizumab"

See other products for "C5"

Select a product category from the dropdown menu below to view related products.
Please select product type
Mouse Antibody Humanized Antibody Neutralizing Antibody Blocking Antibody Rabbit Monoclonal Antibody Human Antibody Recombinant Antibody Fab Fragment Antibody Single-domain Antibody ADCC Enhanced Antibody scFv Fragment Antibody Antibody Magnetic Beads

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for AFC-TAB-008. Click the button above to contact us or submit your feedback about this product.

Popular products with customers


For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare